BIOMAT Database Logo BIOMAT Database Logo

Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. 2015

Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Dept of Cardiology, Keio University School of Medicine, Tokyo, Japan Faculté de Médecine, Université Paris-Sud, Le Kremlin Bicêtre, France Service de Pneumologie, DHU Thorax Innovation, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France Inserm UMR_S 999, LabExLERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France u1@ta-mu.net.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010045 Outpatients Persons who receive ambulatory care at an outpatient department or clinic without room and board being provided. Out-patients,Out patients,Out-patient,Outpatient
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?
December 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
[Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
May 2007, Nihon rinsho. Japanese journal of clinical medicine,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure.
May 2006, Expert opinion on investigational drugs,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
[Tolvaptan (vasopressin receptor antagonist)].
November 2011, Nihon rinsho. Japanese journal of clinical medicine,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
November 2006, The New England journal of medicine,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia.
August 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
November 2007, Biochemical pharmacology,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
[Vasopressin antagonist (Tolvaptan)].
August 2016, Nihon rinsho. Japanese journal of clinical medicine,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure.
January 2013, International heart journal,
Yuichi Tamura, and Mai Kimura, and Makoto Takei, and Tomohiko Ono, and Masataka Kuwana, and Toru Satoh, and Keiichi Fukuda, and Marc Humbert
Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients.
October 2013, Clinical pharmacology and therapeutics,
Copied contents to your clipboard!